Voyager Therapeutics, Inc. (VYGR) Return on equity 2016–2025
Voyager Therapeutics, Inc. (VYGR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-61.1%FY2025 · since FY2016: -29.6% → -61.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -61.1% | -39.4 pp |
| FY2024 | -21.7% | -77.7 pp |
| FY2023 | 56.0% | +134.6 pp |
| FY2022 | -78.6% | -3.7 pp |
| FY2021 | -74.9% | -98.7 pp |
| FY2020 | 23.8% | +67.6 pp |
| FY2019 | -43.8% | +146.3 pp |
| FY2018 | -190.1% | -137.3 pp |
| FY2017 | -52.7% | -23.2 pp |
| FY2016 | -29.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating marginVYGR Operating cash flowVYGR Free cash flowVYGR Capital expendituresVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →